Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
At lowest planned subcutaneous dose, Omeros’ MASP-3 inhibitor OMS906 showed clinically and statistically significant improvements in hemoglobin and LDH, which were seen early and maintained... | April 25, 2023
Omeros Corporation Omeros Corporation Nasdaq Mean Hemoglobin Change Baseline Over Time Business Wire About Omeros
Source: marketscreener.com